I find it hard to believe there won't be multiple interested parties for:
bisPSMA construct, which has nearly proven significantly higher uptake for diagnostics in their bcr combat trial
Cu64/67 pairing that is easily switched in their SAR cage, thus eliminating concerns of diagnostic/therapeutic targeting as well as keeping the payload specific to target.
Grpr targeting allowing for Bombesin and eventually breast
click tech antibody allowing for a massive potential platform
Sartate for GEP NET
CU6 - Media and Industry News, page-181
-
- There are more pages in this discussion • 209 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.62 |
Change
-0.180(3.10%) |
Mkt cap ! $1.817B | |||
| Open | High | Low | Value | Volume |
| $5.89 | $6.10 | $5.62 | $2.990M | 513.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 1745 | $5.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.62 | 128 | 3 |
View Market Depth
| Last trade - 11.22am 07/08/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |